XTX Topco Ltd Boosts Stock Position in BioAtla, Inc. (NASDAQ:BCAB)

XTX Topco Ltd boosted its position in shares of BioAtla, Inc. (NASDAQ:BCAB) by 7.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 154,967 shares of the company’s stock after acquiring an additional 10,384 shares during the quarter. XTX Topco Ltd’s holdings in BioAtla were worth $273,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA lifted its position in shares of BioAtla by 5.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after purchasing an additional 28,133 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in BioAtla during the 3rd quarter worth approximately $623,000. Chicago Partners Investment Group LLC purchased a new position in BioAtla in the 3rd quarter valued at approximately $44,000. Vontobel Holding Ltd. acquired a new position in shares of BioAtla in the third quarter worth $28,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of BioAtla during the second quarter worth $99,000. 77.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the company. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a research note on Monday, September 16th. HC Wainwright downgraded BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

BioAtla Trading Down 9.9 %

Shares of BCAB opened at $1.18 on Thursday. The firm has a market capitalization of $57.05 million, a price-to-earnings ratio of -0.69 and a beta of 0.96. The firm’s fifty day simple moving average is $1.78 and its 200-day simple moving average is $1.71. BioAtla, Inc. has a twelve month low of $1.14 and a twelve month high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter in the previous year, the company posted ($0.70) EPS. On average, analysts predict that BioAtla, Inc. will post -1.49 earnings per share for the current fiscal year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.